Capricor Therapeutics Inc (CAPR) Dividend History

Company News

• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

  Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (CAPR) after the company announced that the FDA will hold an advisory committee meeting for its Biologics License Application, causing the stock price to drop.

  GlobeNewswire Inc.

  Featured Companies: IART PTCT
• CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

  The Schall Law Firm is investigating claims against Capricor Therapeutics, Inc. for potential violations of securities laws. The investigation focuses on whether the company issued false or misleading statements regarding its Biologics License Application for deramiocel, a cell therapy for Duchenne muscular dystrophy cardiomyopathy.

  Benzinga
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

  Capricor Therapeutics, Inc. (CAPR) stock fell 29.13% after the company announced the FDA's intent to hold an advisory committee meeting for its Biologics License Application seeking approval for deramiocel, a cell therapy for Duchenne muscular dystrophy cardiomyopathy.

  GlobeNewswire Inc.
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cable One, Inc. - CABO

  Cable One reported disappointing Q1 2025 earnings, missing analyst expectations and suspending its dividend. The stock price fell over 40% on this news, leading Pomerantz LLP to investigate potential securities fraud or other unlawful business practices by the company and its officers/directors.

  GlobeNewswire Inc.

  Featured Companies: CABO IART
• Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight

  The cell and gene therapies in rare disorders market is expected to grow significantly by 2034, driven by an increase in approvals and adoption of these treatments, ability to treat a broad array of conditions, and rising prevalence of rare disorders.

  GlobeNewswire Inc.

  Featured Companies: ABEO BCLI EDIT FDMT FOLD OCGN PFE RARE RGNX SGMO